Close Menu

NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder. Lexington, Mass.-based SynapDx didn't disclose the amount of the funding from Kraft.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.